Rosalind Workbench

Headlines · 4

1. Oct 21
   OpenAI Acquires AI Drug Research Operations Startup Orchestra Bio

   An Edge AI Daily roundup reports that OpenAI announced the acquisition of AI biotechnology operations software company Orchestra Bio on October 20, 2026. Transaction terms were not disclosed. According to the roundup, Orchestra Bio’s team and technology will join OpenAI’s Rosalind life-science model and Rosalind Workbench to support experiment planning and result analysis. The integration plan was not independently corroborated in the supplied material.

   钛媒体 · 🔥 0
2. Oct 20
   OpenAI acquires Orchestra Bio to add drug-development agents to Rosalind

   OpenAI said it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and will combine its team and technology with Rosalind, OpenAI's AI models and tools for life sciences research. Financial terms were not disclosed; Chinese outlets report Orchestra was founded in San Francisco in 2022 and had raised about $20 million from investors including a16z, 8VC and Insight Partners as of August 2025. OpenAI says Orchestra's agents are designed to track trials and flag affected timelines when something goes wrong, such as a failed production batch, and that Rosalind already counts Moderna and Novo Nordisk as customers. OpenAI frames the deal as a step toward agents that connect scientific findings with the studies, decisions and next steps needed to advance a potential medicine.

   OpenAI · 🔥 0
3. Oct 15
   OpenAI launches Rosalind Academic Plan with up to 30 free GPT-Rosalind seats

   OpenAI introduced the Rosalind Academic Plan, which gives academic labs at U.S. universities up to 30 Business Standard seats at no cost for up to 12 months, centered on GPT-Rosalind, its life-sciences model, plus the Rosalind Workbench for tool orchestration across medicinal chemistry, genomics and wet-lab assistance. Access requires trusted-access approval: OpenAI verifies the institution, the PI or lab lead and the intended use, then continues monitoring, with safety checks that account for approved research context in registered high-sensitivity cases and follow-ups when use is unclear. OpenAI says research data shared through the plan is not used to train its models by default, API access is not included, and labs at universities with an existing enterprise agreement must apply through that process.

   OpenAI · 🔥 0
4. Oct 10
   OpenAI pricing page lists unannounced gpt-rosalind-discovery life sciences model

   TestingCatalog reported that OpenAI's API pricing page now lists an unannounced model, gpt-rosalind-discovery, under a "Life sciences models" section next to the already public gpt-rosalind-research, with identical pricing of $5 per million input tokens, $0.50 per million cached input tokens and $25 per million output tokens. There is still no blog post, help article or system card for it, and MIT Technology Review China said the model documentation pages return 404 errors, leaving pricing as the only published information. Outside observers guess from the "discovery" name that it targets drug discovery, but its purpose, its relationship to the research model and any real gains remain undisclosed.

   TestingCatalog · 🔥 0

Experience and discussion from the community

Share my Rosalind Workbench experienceAsk about Rosalind Workbench